Form D · Biotechnology
Oncotelic Therapeutics, Inc.
Agoura Hills, CA · CIK 0000908259
Offering snapshot reported Jul 22, 2026 · SEC filing
- Reported sold
- $712K Offering amount: $712K
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2026 | Initial | $711,840 | No comparison | 33 | SEC filing |
| Dec 11, 2025 | Initial | $275,000 | No comparison | 4 | SEC filing |
| Jul 13, 2023 | Initial | Yet to sell | No comparison | 15 | SEC filing |
| Aug 4, 2020 | Initial | $2,000,000 | No comparison | 24 | SEC filing |
| May 7, 2019 | Initial | $27,000,000 | No comparison | 26 | SEC filing |
| May 7, 2019 | Initial | $600,000 | No comparison | 4 | SEC filing |
| Apr 25, 2018 | Initial | $2,925,000 | No comparison | 38 | SEC filing |
| Mar 26, 2010 | Initial | $7,500,000 | No comparison | 5 | SEC filing |
| Nov 4, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-591797
RSUs, CONVERTIBLE INTO CONV. SERIES A PREF. SHARES, THEN INTO COMMON STOCK. GRANTED TO D&Os, EMPOYEES AND ADVISORS FOR SERVICES TO THE COMPANY. RSUs ARE CONTINGENT UPON ACHIEVEMENT OF CERTAIN CORPORATE MILESTONES
RSUs, CONVERTIBLE INTO CONV. SERIES A PREF. SHARES, THEN INTO COMMON STOCK. GRANTED TO D&Os, EMPOYEES AND ADVISORS FOR SERVICES TO THE COMPANY. RSUs ARE CONTINGENT UPON ACHIEVEMENT OF CERTAIN CORPORATE MILESTONES
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| N.A. | None |
Source: Form D, filed Jul 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shah Amit | Executive |
| David J. Chaplin | Director, Executive |
| Seymour Fein | Executive |
| Roy H. Fickling | Director |
| Mark Kessel | Director |
| Steven King | Director |
| Peter J. Langecker | Executive |
| Matthew Loar | Executive |
| Anthony Maida | Director, Executive |
| James B. Murphy | Executive |
| Chulho Park | Executive |
| Chuho Park | Executive |
| Simon C. Pedder | Director |
| Donald R. Reynolds | Director |
| Bobby W. Sandage, Jr. | Director |
| Saran Saund | Executive |
| William Schwieterman | Director |
| Amit Shah | Executive |
| William N. Shiebler | Director |
| Vuong Trieu | Director, Executive |
| Fatih Uckun | Executive |
| Alastair J.J. Wood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
29397 Agoura Road Suite 107
Agoura Hills, CA, 91301
Phone: 650-635-7000
Agoura Hills, CA, 91301
Phone: 650-635-7000